Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Activated FGFR3 point and translocation mutants bind PLCG1

Class:Id	Reaction:5655244
_displayName	Activated FGFR3 point and translocation mutants bind PLCG1
_doRelease	TRUE
_timestamp	2021-10-28 16:30:54
authored	[InstanceEdit:2105031] Rothfels, K, 2012-02-09
compartment	[Compartment:876] plasma membrane
created	[InstanceEdit:5655319] Rothfels, Karen, 2014-12-05
disease	[Disease:2032940] bone development disease [Disease:1500689] cancer
edited	[InstanceEdit:2252592] Rothfels, K, 2012-05-16
entityFunctionalStatus	[EntityFunctionalStatus:9757294] gain_of_function of Activated FGFR3 point and translocation mutants [plasma membrane]
input	[DefinedSet:5655234] Activated FGFR3 point and translocation mutants [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:167682] PLCG1 [plasma membrane] [Homo sapiens] [SimpleEntity:179838] PI(3,4,5)P3 [plasma membrane]
literatureReference	[LiteratureReference:191028] Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells [LiteratureReference:190978] Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F [LiteratureReference:2060759] Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner [LiteratureReference:2077411] FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies [LiteratureReference:2029811] Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis [LiteratureReference:2033242] Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma [LiteratureReference:1295608] Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
modified	[InstanceEdit:9753842] Rothfels, Karen, 2021-09-15 [InstanceEdit:9757295] Rothfels, Karen, 2021-10-28 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Activated FGFR3 point and translocation mutants bind PLCG1
normalReaction	[Reaction:5654224] Activated FGFR3 binds PLCG1 [Homo sapiens]
output	[Complex:5655305] Activated FGFR3 point and translocation mutants: PLCG1 [plasma membrane] [Homo sapiens]
releaseDate	2012-06-12
reviewed	[InstanceEdit:2248845] Ezzat, S, 2012-05-15
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:5680361] R-HSA-5655244.3
summation	[Summation:2077542] Although it has not been rigourously established, there is s...
(hasEvent)	[Pathway:5655332] Signaling by FGFR3 in disease [Homo sapiens]
(replacementInstances)	[_Deleted:5655674] Deletion of instance: 2077380
[Change default viewing format]

No pathways have been reviewed or authored by Activated FGFR3 point and translocation mutants bind PLCG1 (5655244)